The thiouracil derivative PF-06282999 [2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide] is an irreversible inactivator of myeloperoxidase and is currently in clinical trials for the potential treatment of cardiovascular diseases. Concerns over idiosyncratic toxicity arising from bioactivation of the thiouracil motif to reactive species in the liver have been largely mitigated through the physicochemical (molecular weight, lipophilicity, and topological polar surface area) characteristics of PF-06282999, which generally favor elimination via nonmetabolic routes. To test this hypothesis, pharmacokinetics and disposition studies were initiated with PF-06282999 using animals and in vitro assays, with the ultimate goal of predicting human pharmacokinetics and elimination mechanisms. Consistent with its physicochemical properties, PF-06282999 was resistant to metabolic turnover from liver microsomes and hepatocytes from animals and humans and was devoid of cytochrome P450 inhibition. In vitro transport studies suggested moderate intestinal permeability and minimal transporter-mediated hepatobiliary disposition. PF-06282999 demonstrated moderate plasma protein binding across all of the species. Pharmacokinetics in preclinical species characterized by low to moderate plasma clearances, good oral bioavailability at 3-to 5-mg/kg doses, and renal clearance as the projected major clearance mechanism in humans. Human pharmacokinetic predictions using single-species scaling of dog and/or monkey pharmacokinetics were consistent with the parameters observed in the first-inhuman study, conducted in healthy volunteers at a dose range of 20-200 mg PF-06282999. In summary, disposition characteristics of PF-06282999 were relatively similar across preclinical species and humans, with renal excretion of the unchanged parent emerging as the principal clearance mechanism in humans, which was anticipated based on its physicochemical properties and supported by preclinical studies.
Introduction
The hemoprotein myeloperoxidase (MPO; EC 1.11.1.7), produced in the bone marrow, is one of the major neutrophil bactericidal proteins. MPO has recently emerged as a critical modulator of inflammatory conditions including rheumatoid arthritis (Odobasic et al., 2014) , chronic obstructive pulmonary disease (Churg et al., 2012) , acute kidney injury (Odobasic et al., 2007 ), Parkinson's disease (Choi et al., 2005) , and cardiovascular disease (Mayyas et al., 2014) . High concentrations of MPO have been detected in atherosclerotic plaques (Hazell et al., 1996) and elevated MPO levels are associated with risk of cardiovascular disease in otherwise healthy individuals (Meuwese et al., 2007) . Studies in MPO knockout mice have demonstrated protection from cardiac remodeling and impaired left ventricular function after surgically induced myocardial infarction (Penn, 2008) .
The identification of MPO as a central player in inflammation renders this enzyme as a potential target for therapeutic interventions. Our laboratory recently described the design, synthesis, and preclinical characterization of some novel N1-substituted-6-aryl-2-thiouracil analogs as mechanism-based inactivators of MPO, which culminated in the discovery of the clinical candidate PF-06282999 [2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl) acetamide] (Fig. 1) (Ruggeri et al., 2015) . PF-06282999 is a suicide substrate of MPO with a high degree of selectivity relative to other peroxidases such as thyroid peroxidase. The inhibitory mechanism likely involves oxidation of the thiouracil sulfur atom in PF-06282999 by the compound I intermediate of oxidized MPO to yield a thiyl radical, which covalently attaches to the heme moiety, causing enzyme inactivation (Ruggeri et al., 2015) . The mode of inhibition is similar to the one described with the recently reported 2-thioxanthine class of MPO inactivators (e.g., compound TX5 in Fig. 1 ) (Tidén et al., 2011; Geoghegan et al., 2012) .
From a drug design perspective, thiouracils and related analogs (e.g., thioureas and thioamides) are structural alerts, which can be metabolically activated by MPO, cytochrome P450 (P450 enzymes), and flavin monooxygenases to electrophilic sulfenic acid and sulfonate intermediates, which are capable of covalently modifying proteins and eliciting a toxicological outcome (Hanzlik and Cashman, 1983; Henderson et al., 2004) . For instance, immunemediated hepatotoxicity and agranulocytosis associated with the clinical use of the antithyroid agent propylthiouracil has been causally linked to the oxidative bioactivation of thiouracil functionality by MPO to yield protein-reactive propylthiouracil-2-sulfenic acid and propylthiouracil-2-sulfonate metabolites, which induce the formation of the antineutrophil antibodies in patients with propylthiouracilinduced agranulocytosis (Lee et al., 1988; Waldhauser and Uetrecht, 1991) . The risk of wayward electrophilic species arising from MPOcatalyzed oxidation of PF-06282999 was principally mitigated on the basis of its low partition ratio (approximately 7.0) for MPO inactivation, which is in contrast with the very high partition ratio of 75 obtained with propylthiouracil (Ruggeri et al., 2015) . Correspondingly, no glutathione conjugates of PF-06282999 were detected in incubations with recombinant human MPO/hydrogen peroxide incubations (Ruggeri et al., 2015) . Likewise, reductions in lipophilicity and molecular weight in the thiouracil class of MPO inhibitors ensured that the compounds were latent toward oxidative metabolism (including bioactivation) in the liver (Ruggeri et al., 2015) .
A thorough understanding of major clearance pathways and accurate prediction of human pharmacokinetics of drug candidates is a critical endeavor in drug discovery, given the intrinsic links with clinical pharmacology and/or safety, which continue to dominate attrition rates in drug development (Kola and Landis, 2004; Hay et al., 2014) . Consequently, in preparation for preclinical toxicological and first-inhuman clinical studies for assessment of safety, tolerability, and pharmacokinetics, the disposition of PF-06282999 was examined in animals and in vitro human models. This work summarizes the preclinical absorption, distribution, metabolism, and excretion profile of PF-06282999. Results from the preclinical studies were used to predict human pharmacokinetics including the identification of anticipated clearance pathways. The collective findings are discussed against the backdrop of the single-dose pharmacokinetics and major elimination mechanism of PF-06282999 in healthy human volunteers after oral (p.o.) administration. Plasma Protein Binding. The extent of binding of PF-06282999 to rat (five males/five females), mouse (30 males/30 females), dog (five males/five females), monkey (five males/five females), and human (at least three males and three females) plasma proteins was determined using a disposable rapid equilibrium dialysis device with prepacked inserts (ThermoScientific, West Palm Beach, FL). Plasma samples were prepared by mixing PF-06282999 with plasma to produce a final incubation concentration of 2 mM for PF-06282999. Aliquots (220 ml; n = 4) of spiked plasma were added to the donor wells, followed by the addition of phosphate-buffered saline (350 ml; n = 4) to the receiver wells. The device was covered with a gas permeable membrane and agitated on an orbital shaker at approximately 450 rpm within a humidified incubator (75% relative humidity, 5% CO 2 ) operating at 37°C for 4 hours. Control plasma samples (t = 0, 15 ml, n = 2) were prepared from the remaining spiked plasma solution. Each sample was matrix matched with buffer (45 ml) and plasma (15 ml). The samples were precipitated with a 120-ml acetonitrile solution containing 100 ng/ml CP-628374 as the internal standard. All samples for analysis were prepared in a 96-well plate, centrifuged (1900 Â g, 5 minutes, room temperature), and the supernatants were transferred and analyzed by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The fraction unbound of PF-06282999 to plasma proteins was calculated as the ratio of concentration of analyte in buffer over concentration of analyte in plasma.
Blood Cell Partitioning. Blood to plasma partitioning of PF-06282999 was determined in fresh rat, mouse, dog, monkey, and human whole blood and plasma to which PF-06282999 was added to yield a final concentration of 1 mM (n = 3). Samples were incubated on an orbital shaker in a humidified CO 2 incubator for 60 minutes at 37°C. After incubation, whole blood samples were either centrifuged to obtain plasma or matrix matched with appropriate blank plasma. Aliquots (20 ml) of plasma sample incubations and either plasma isolated from whole blood or matrix-matched whole blood were mixed with acetonitrile (200 ml) containing CP-628374 (100 ng/ml, internal standard) and centrifuged. Supernatants were analyzed using LC-MS/MS. A blood/plasma partitioning ratio for PF-06282999 was calculated from the concentrations in blood and plasma.
In Vitro Permeability Studies. Apparent permeability (P app ) of PF-06282999 was examined in Caco-2 and low-efflux Madin-Darby canine kidney (MDCKII-LE) cell lines in triplicate using previously published protocols (Frederick et al., 2009; Di et al., 2011; Varma et al., 2011) . MDCKII-LE cells were established in house and the cell culture and experimental procedures were discussed in detail previously (Di et al., 2011) . Caco-2 cells, obtained from the American Type Culture Collection (Manassas, VA), were seeded in 24-well Falcon multiwell plates (polyethylene terephthalate membranes, pore size 1 mm) (Thomas Scientific, 
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Swedesboro, NJ) at 4 Â 10 4 cells/well. Caco-2 absorptive permeability was assessed at apical/basal pH of 6/7.4 and 7.4/7.4. The effect of calcium-free medium and efflux inhibitor cocktail, cyclosporin A (7 mM) and verapamil (40 mM), on absorptive permeability (pH 7.4/7.4) of PF-06282999 (1 mM) was also evaluated. Permeability of nadolol, a low permeability marker, was measured to assess the cell monolayer integrity.
Human MDCKII-MDR1 Efflux Assay. MDCKII-multidrug-resistant gene 1 (MDR1) cells were obtained from Dr. Piet Borst (Netherland Cancer Institute, Amsterdam, The Netherlands). The cells were seeded at a cell density of 2.5 Â 10 5 cells/ml in complete minimum Eagle's medium/a medium on Falcon/BD 96-well membrane inserts and incubated (37°C, 95% humidity, 5% CO 2 ) for 5 days. A transwell assay analogous to the one previously described (Feng et al., 2008a) was used. For apical-to-basolateral permeability (P app,AB ), medium was removed from the insert on day 5. Seventy-five microliters of fresh Hanks' balanced salt solution (HBSS) with added components (Life Technologies, Grand Island, NY) containing PF-06282999 (2 mM) was added on the apical side and 250 ml fresh buffer was added on the basolateral side. The plate was then incubated at 37°C for 2 hours. For basolateral-to-apical permeability, medium from the insert was replaced with 75 ml fresh buffer and 250 ml fresh buffer containing PF-06282999 (2 mM) was added on the basolateral side, followed by incubation for 2 hours at 37°C. All studies with PF-06282999 were conducted in triplicate.
The following equations were used to calculate P app values and the MDR1 efflux ratio:
Efflux ratio ¼ P app;BA P app;AB where area is the surface area of the transwell insert, C D (0) is the initial concentration of compound applied to the donor chamber, t is incubation time, M r is the mass of the compound in the receiver compartment, dM r /dt is the flux of the compound across the cell monolayer, and P app,BA is the basolateral-to-apical permeability. Liver Microsomal Stability. Pooled male Wistar-Han rat, male CD-1 mouse, male beagle dog, male cynomolgus monkey, and male and female human liver microsomes (pool of 50 livers) were purchased from BD Gentest (Woburn, MA). Half-life (t 1/2 ) assessments in liver microsomes was determined in duplicate after incubation of PF-06282999 (1 mM) with liver microsomes (P450 concentration = 0.25 mM) in 0.1 M potassium phosphate buffer (pH 7.4) containing 1 mM MgCl 2 at 37°C. The reaction mixture was prewarmed at 37°C for 2 minutes before adding NADPH (1.3 mM). Aliquots of the reaction mixture at 0, 5, 10, 15, 30, 45 , and 60 minutes were added to acetonitrile containing an internal standard (100 ng/ml CP-628374), and the samples were centrifuged before LC-MS/MS analysis of substrate disappearance. For control experiments, NADPH and/or liver microsomes were omitted from these incubations. For the purposes of metabolite identification studies, the concentration of PF-06282999 in the microsomal incubations was raised to 10 mM and the microsomal protein concentration increased to 1 mg/ml. The duration of the incubation time was 45 minutes. Separate incubations of PF-06282999 (10 mM) were also conducted in human liver microsomes containing NADPH (1.3 mM) and glutathione (1 mM) for the purposes of trapping reactive species arising from the oxidative metabolism of PF-06282999.
Stability in Cryopreserved Hepatocytes. Cryopreserved Wistar-Han rat (male, pool of 12 donors), CD-1 mouse (male, pool of 12 donors), beagle dog (male, pool of five donors), cynomolgus monkey (male, pool of five donors), and human (pool of 10 donors of mixed sex) hepatocytes were purchased from Celsis (Chicago, IL). Williams' E media was prepared by adding 26 mM sodium bicarbonate and 50 mM HEPES, followed by 0.2-mm filtration and then 30 minutes of CO 2 /O 2 bubbling at 37°C. This medium was used for thawing suspension of hepatocytes. Incubations were conducted in a 96-well flat-bottom polystyrene plate in duplicate. Hepatocytes were suspended at 0.5 Â 10 6 viable cells/ml of Williams' E media and prewarmed at 37°C for 30 minutes. Incubations were initiated with the addition of PF-06282999 (final concentration = 1 mM) and were conducted at 37°C, 75% relative humidity, and 5% CO 2 . The reaction was stopped at 0, 3, 15, 30, 60, 90, or 120 minutes by the addition of acetonitrile (135 ml) containing an internal standard. The samples were centrifuged at approximately 1900 Â g for 10 minutes before LC-MS/MS analysis for the disappearance of PF-06282999. For the purposes of qualitative metabolite identification studies, the concentration of PF-06282999 in the hepatocyte incubations was increased to 10 mM.
For examination of PF-06282999 depletion in cryopreserved human hepatocytes via the relay method (Di et al., 2013) , the hepatocyte plate was incubated at 37°C with 95% O 2 /5% CO 2 and 75% relative humidity for 4 hours daily for 5 days. Aliquots (25 ml) of the total suspension were sampled at 0, 4, 8, 12, 16, and 20 hours and the rest of the hepatocyte incubation plate was centrifuged (approximately 1900 Â g, 10 minutes, room temperature) at the end of each relay. Aliquots (50 ml) of supernatant were sampled for quantification of concentration and 300 ml supernatant was transferred to a clean 24-well plate and stored at 280°C until the next relay experiment. For the second relay experiment, the supernatant plate was warmed to 37°C for 30 minutes and hepatocytes were added to the samples to give a final cell density of 0.5 Â 10 6 cells/ml. The plates were incubated at 37°C for 4 hours, sampled, and processed as described above. All of the samples were quenched with 2Â volume of acetonitrile containing an internal standard, centrifuged, and transferred for LC-MS/MS analysis. Five relays were performed to give a total incubation time of 20 hours, and t 1/2 was calculated as described in the microsomal stability section. The following equations were used to calculate apparent intrinsic clearance, scaled intrinsic clearance, and hepatic blood clearance :
where CL int,app is apparent intrinsic clearance, CL int,scaled is scaled intrinsic clearance, CL b is hepatic blood clearance, Q is human hepatic blood flow (20 ml/min/kg), f up is unbound fraction in plasma, R b is blood to plasma ratio CLu, int is unbound intrinsic clearance, and f umic is unbound fraction in liver microsomes. Transport Studies Using Sandwich Culture Human Hepatocytes. Cryopreserved human hepatocyte lot Hu4241 was obtained from Life Technologies. The sandwich culture human hepatocyte (SCHH) methodology applied here was described previously (Bi et al., 2006) . Briefly, cryopreserved hepatocytes were thawed and plated with a cell density of 0.75 Â 10 6 cells/ml. The plates were overlaid with 0.25 mg/ml matrigel on the second day and the cultures were maintained. On day 5, the hepatocytes were preincubated for 10 minutes with Ca 2+ HBSS buffer in the absence or presence of rifamycin SV (100 mM) for determination of apparent intrinsic uptake clearance. For determination of apparent intrinsic biliary clearance, the cells were preincubated with or without Ca 2+ HBSS buffer for 10 minutes. After aspiration of the preincubation buffer, the reactions were initiated by addition of PF-06282999 (1 mM) and were terminated at predetermined time points (0.5, 1, 2, 5, 10, and 15 minutes) by washing the cells three times with ice-cold HBSS. Cells were then lysed with 100% methanol containing terfenadine as the internal standard and the samples were analyzed by LC-MS/MS. Calculation of the apparent intrinsic uptake clearance, passive diffusion, apparent intrinsic biliary clearance, and biliary excretion index was described in detail previously (Kalgutkar et al., 2007) .
P450 Inhibition Studies. Reversible inhibition of major human P450 isoforms (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5) by PF-06282999 was evaluated via incubation of standard marker substrates [phenacetin (CYP1A2), bupropion (CYP2B6), paclitaxel (CYP2C8), diclofenac (CYP2C9), S-mephenytoin (CYP2C19), dextromethorphan (CYP2D6), testosterone (CYP3A4/5), midazolam (CYP3A4/5), and nifedipine (CYP3A4/5)] of human P450 isozymes with pooled human liver microsomes in the presence of an NADPH-regenerating system [NADP (1 mM), glucose-6-phosphate (5 mM), and glucose-6-phosphate dehydrogenase (1 U/ml)] in 50 mM potassium phosphate buffer (pH 7.4) containing 3.3 mM MgCl 2 and 1 mM EDTA at 37°C open to air. The incubation volume was 0.2 ml. Microsomal protein concentrations, substrate concentrations, incubation times, and reaction termination solvents for each activity have been described in detail previously dmd.aspetjournals.org (Walsky and Obach, 2004) . Incubation mixtures contained PF-06282999 at concentrations ranging from 0.1 to 100 mM. Stock solutions of PF-06282999 were prepared in methanol. The final concentration of methanol in the incubation mixtures was 1% (v/v).
To examine the ability of PF-06282999 to act as a time-and/or NADPHdependent inhibitor of major human P450 isoforms, PF-06282999 (0-100 mM) was preincubated at 37°C, in duplicate, with human liver microsomes (protein concentration 50-100 mg/ml, depending on which isozyme was assessed) in 50 mM potassium phosphate buffer (pH 7.4) containing 3.3 MgCl 2 and 1 mM EDTA at 37°C in the presence and absence of an NADPH-regenerating system for approximately 30 minutes. After preincubation, a portion of the incubation mixture (20 ml) was added to a mixture containing a probe P450 isozyme substrate (concentration of approximately the K m value) (Walsky and Obach, 2004) in 50 mM potassium phosphate buffer (pH 7.4) containing 3.3 mM MgCl 2 , 1 mM EDTA, and the NADPH-regenerating system at 37°C. At the end of the incubation period (30 minutes), acetonitrile containing an internal standard was added, and the mixtures were centrifuged (920 Â g, 10 minutes, 10°C). The supernatants were analyzed by LC-MS/MS for metabolites of probe P450 substrates using validated bioanalytical conditions established previously (Walsky and Obach, 2004) . IC 50 values for inhibition of P450 isozymes were estimated using Galileo software (version 3.3; ThermoFisher Scientific Inc., Philadelphia, PA).
Human Renal Transporter Substrate Studies. Human embryonic kidney (HEK) 293 cells transfected with the human renal transporter proteins organic cation transporter 2 (hOCT2), organic anion transporter 1 (hOAT1), or organic anion transporter 3 (hOAT3) were generated at Pfizer. Wild-type HEK 293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum. HEK-hOAT1, HEK-hOAT3, and HEKhOCT2 cells were cultured using growth media containing hygromycin B (60 mg/ml). Cells were maintained at 37°C, 5% CO 2 , and 95% relative humidity. Uptake studies used our previously published protocol (Feng et al., 2008b) . Briefly, cells were seeded at a density of 1.12 Â 10 5 cells/well in 24-well poly(Dlysine)-coated plates and were cultured for 48 hours. Uptake buffer was prepared using HBSS, supplemented with 20 mM HEPES, at pH 7.4. Uptake was initiated by the addition of 0.1 ml uptake buffer containing varying concentrations (0.137-300 mM) of PF-06282999. The plates were then incubated for 4 minutes at 37°C with shaking at 150 rpm. The experiment was stopped by washing the cells four times with 0.2 ml ice-cold uptake buffer/well, and then lysed with 0.2 ml internal standard solution in 100% methanol. The lysates were analyzed by LC-MS/MS for PF-06282999.
Animal Pharmacokinetics. All experiments involving animals were conducted in our AAALAC-accredited facilities and were reviewed and approved by the Pfizer Institutional Animal Care and Use Committee. Male CD-1 mice (25-35 g), jugular vein/carotid artery double cannulated Wistar-Han rats (approximately 250 g; obtained from Charles River Laboratories, Wilmington, MA), male beagle dogs (approximately 12 kg), and male cynomolgus monkeys (approximately 7 kg) were used for these studies. Animals were fasted overnight and through the duration of the study (1 or 2 hours), whereas access to water was provided ad libitum. PF-06282999 was administered intravenously (i.v.) in either 12% sulfobutylether-b-cyclodextrin with or without 1% dimethylsulfoxide or 30% hydroxypropyl-b-cyclodextrin containing 5% dimethylsulfoxide via the tail vein (mice, n = 3), carotid artery (rats, n = 3), saphenous vein (dogs, n = 3), or femoral vein (monkeys, n = 2) at a dose of 1 mg/kg in a dosing volume of 5 ml/kg (mice), 2 ml/kg (rats), 0.5 ml/kg (dogs), and 1 ml/kg (monkeys). Serial blood samples were collected before dosing and 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours after dosing. PF-06282999 was also administered by p.o. gavage to mice (5 mg/kg at 5 ml/kg in 0.5% methylcellulose), rats (5 mg/kg at 2.5 ml/kg in 0.5% methylcellulose), dogs (3 mg/kg at 3 ml/kg in 0.5% methyl cellulose), and monkeys (3 mg/kg at 5 ml/kg in 5% hydroxypropyl methylcellulose in 20 mM Tris/0.5% hydroxypropyl methylcellulose acetate succinate). Blood samples were taken prior to p.o. administration then serial samples were collected at 0.25, 0.5, 1, 2, 4, 7, and 24 hours after dosing. Blood samples from the various pharmacokinetic studies were centrifuged to generate plasma. All plasma samples were kept frozen until analysis. Urine samples (0-7 and 7-24 hours; pooled 0-24 hours for mice) were also collected after i.v. administration to mice, rats, dogs, and monkeys. For mouse samples, aliquots of plasma (10 ml) or urine (2 ml mixed with 8 ml plasma) were extracted using liquid/liquid extraction with methyl-t-butyl ether containing an internal standard. For rat, dog, or monkey samples, aliquots of plasma or urine (20-25 ml) were transferred to 96-well blocks and acetonitrile (150-200 ml) containing an internal standard was added to each well. The supernatant was dried under nitrogen and reconstituted with 100 ml acetonitrile/water (1:1 with 0.1% formic acid for mice; 20:80 for dogs) or added to 100 ml water without evaporation. After extraction, the samples were then analyzed by LC-MS/MS and concentrations of analyte in plasma and urine were determined by interpolation from a standard curve.
Pharmacokinetics Studies in Humans. The phase I first-in-human study was an investigator-and subject-blinded (sponsor-open), randomized, placebocontrolled crossover study of ascending single p.o. doses of PF-06282999 administered sequentially, at least 1 week apart, in healthy adult subjects. The study protocol and informed consent documents were approved by the institutional review board. All subjects signed an approved written informed consent form before any study-related activities for this clinical study. All subjects were male, and the majority were white (n = 7 of 8, 87.5%) and of Hispanic or Latino descent. Age ranged from 22 to 46 years. Weight ranged from 70.5 to 98.2 kg, and body mass index ranged from 23 to 30.3 kg/m 2 across the treatment groups. No dose-limiting tolerability was noted over the dose range of 20-200 mg. PF-06282999 was administered as a solution [1% (w/v) methylcellulose, 0.5% (w/v) hydroxypropyl methylcellulose acetate succinate-HF, and 80 mM tromethamine with a small amount of sodium hydroxide] to one cohort of eight fasted male subjects at doses of 20, 50, 125, and 200 mg in a four-period, four-sequence crossover treatment design with placebo substitution (Table 1) . Within each treatment period, six subjects were randomized to the active study drug and two were randomized to a matching placebo. A standardized meal was provided 4 hours after dosing. Blood samples were collected at intervals for up to 48 hours postdose for quantitation of circulating levels of PF-06282999. Two urine samples were collected from 0 to 24 hours pre-and postdose, the volume was measured, and aliquots were examined quantitatively for PF-06282999.
Determination of Pharmacokinetic Parameters. Pharmacokinetic parameters in animals and humans were determined using noncompartmental analysis (a Pfizer internally validated system of noncompartmental analysis for human data; Watson version 7.4 was used for animal data; Thermo Scientific, Waltham, MA). Maximum plasma concentrations (C max ) of PF-06282999 in plasma after p.o. dosing in preclinical species and humans were determined directly from the experimental data, with T max defined as the time of first occurrence of C max . The area under the plasma concentration-time curve (AUC) from t = 0 to 24 hours (AUC 0-24 ) and t = 0 to infinity (AUC 0-' ) was estimated using the linear trapezoidal rule. In animals, systemic plasma clearance (CL p ) was calculated as the intravenous dose divided by AUC 0-' i.v. . In humans, apparent p.o. clearance (CL/F) was calculated as the p.o. dose divided by AUC 0-' p.o.
. The terminal rate constant (k el ) was calculated by a linear regression of the log-linear concentration-time curve, and the terminal elimination t 1/2 was calculated as 0.693 divided by k el . Apparent steady-state distribution volume (Vd ss ) in animals and apparent volume of distribution (V z /F) in humans were determined as the i.v. or p.o. dose divided by the product of AUC 0-' and k el . The absolute bioavailability (F) of the p.o. doses in animals was calculated by using the following equation:
. The percentage of unchanged PF-06282999 excreted in urine over 24 hours [A e,urine,(0-24 h) ] was calculated using the following equation: amount (in milligrams) of PF-06282999 in urine over the 24-hour interval postdose/actual amount of PF-06282999 dose administered (in milligrams) Â 100%. The renal clearance (CL renal ) was derived as the ratio of amount (in milligrams) of PF-06282999 in urine over the 24-hour interval postdose/AUC 0-24 h .
LC-MS/MS Analysis for Quantitation of PF-06282999. Concentrations of PF-06282999 were determined on an AB Sciex model API-4000 LC-MS/MS triple quadrupole mass spectrometer (AB Sciex, Framingham, MA). Analytes were chromatographically separated using an Eksigent Express HT (Eksigent Technologies, Dublin, CA) or Shimadzu LC-20AD (Shimadzu Scientific Instruments, MD) pumps. A CTC PAL autosampler (Agilent, Santa Clara, CA) was programmed to inject 20 ml on a Luna C8 (3 m) 30 Â 2 mm for rats or a kinetex C18 (2.6 m) 30 Â 3 mm for mice, using a mobile phase consisting of 10 mM ammonium formate buffer containing 0.1% (v/v) formic acid (solvent A) and acetonitrile (solvent B) at a flow rate of 0.5 ml/min. Ionization was conducted in the positive ion mode at the ionspray interface temperature of 400°C, using nitrogen for nebulizing and heating gas. The ion spray voltage was 5.0 kV and the declustering potential was optimized at 41 eV. PF-06282999 was detected using electrospray ionization in the multiple reaction monitoring mode monitoring for a mass-to-charge ratio (m/z) transition 326→155. PF-06282999 standards were fit by least-squares regression of their areas to a weighted linear equation, from which the unknown concentrations were calculated. The dynamic range of the assay was 1-2000 ng/ml. Assay performance was monitored by the inclusion of quality control samples with acceptance criteria of 630% target values. Bioanalytical Methodology for Metabolite Identification. Qualitative assessment of the metabolism of PF-06282999 in liver microsomes and hepatocytes was conducted using a Thermo Finnegan Surveyor photodiode array plus detector, a Thermo Acela pump, and a Thermo Acela Autosampler (ThermoScientific). Chromatography was performed on a Phenomenex Hydro RP C18 (4.6 mm Â 150 mm, 3.5 mm) column (Phenomenex, Torrance, CA). The mobile phase was composed of 5 mM ammonium formate buffer with 0.1% formic acid (pH 3) (solvent A) and acetonitrile (solvent B) at a flow rate of 1 ml/min. The binary gradient was as follows: the solvent A to solvent B ratio was held at 95:5 (v/v) for 3 minutes and then adjusted to 55:45 (v/v) from 0 to 35 minutes, 30:70 (v/v) from 35 to 45 minutes, and 5:95 (v/v) from 45 to 52 minutes, where it was held for 3 minutes and then returned to 95:5 (v/v) for 6 minutes before the next analytical run. Identification of the metabolites was performed on a Thermo Orbitrap mass spectrometer operating in positive ion electrospray mode. The spray potential was 4 V and the heated capillary was at 275°C. Xcalibur software (version 2.0; Thermo Scientific) was used to control the HPLC-mass spectrometry system. Product ion spectra were acquired at a normalized collision energy of 65 eV with an isolation width of 2 atomic mass units. Metabolites from liver microsomes or hepatocyte incubations were identified in the full-scan mode (from m/z 100 to 850) by comparing t = 0 samples with t = 45 minute (liver microsomes) 240-minute (hepatocyte) samples or through comparison with synthetic standards, and structural information was generated from the collisioninduced dissociation spectra of the protonated molecular ions (MH + ). Pharmacokinetics Projections to Humans. The single-species allometric method was used to predict human pharmacokinetic parameters of PF-06282999 (Frederick et al., 2009) . CL p and Vd ss observed in preclinical species were corrected for species differences in plasma protein binding and then scaled to humans (Frederick et al., 2009) . This approach uses a fixed allometric exponent of 0.75 and 1 for clearance and volume, respectively. Renal clearance in humans was predicted from rats, dogs, and monkeys using the direct correlation methodology reported previously (Paine et al., 2011) . Rat, dog, or monkey CL renal values corrected for plasma protein binding and kidney blood flow (KBF) differences were used to predict human CL renal using the following equation:
where f u is fraction unbound in plasma. Values used for rat, dog, monkey, and human KBF were 52 (Hsu et al., 1975) , 22 (Keil et al., 1989) , 28 (Davies and Morris, 1993) , and 16 ml/min per kilogram (Wolf et al., 1993) , respectively.
Results
Plasma Protein Binding and Blood Cell Partitioning of PF-06282999. In vitro plasma protein binding of PF-06282999 was evaluated by equilibrium dialysis in rat, mouse, dog, monkey, and human plasma. The mean fraction unbound in mouse rat, dog, monkey, and human plasma was 0.451, 0.447, 0.460, 0.536, and 0.376, respectively, indicating that PF-06282999 is moderately bound to plasma proteins across preclinical species and humans. PF-06282999 was stable in mouse, rat, dog, monkey, and human plasma for more than 4 hours at 37°C at the concentrations used in the plasma free fraction determination. The blood/plasma ratios for PF-06282999 were 1.1, 1.1, 0.91, 1.2, and 0.94 in mice, rats, dogs, monkeys, and humans, respectively, suggesting that PF-06282999 was equally distributed into plasma and red blood cells.
Metabolic Stability Studies with PF-06282999. PF-06282999 (1 mM) did not show metabolic turnover in NADPH-supplemented liver microsomes (t 1/2 . 120 minutes) and cryopreserved hepatocytes (t 1/2 . 240 minutes) from rats, mice, dogs, monkeys, and humans in the time course of incubation (60 minutes for liver microsomes and 120 minutes for hepatocytes). Furthermore, no metabolic turnover was noted in PF-06282999 (1 mM) incubations in the cryopreserved human hepatocyte assay under relay conditions (t 1/2 . 2400 minutes; CL int,scaled , 1.46 ml/min per kilogram, hepatic blood clearance , 0.57 ml/min per kilogram) (Di et al., 2013) . Consistent with these findings, qualitative examination of metabolites in liver microsomes and hepatocytes from rats, mice, dogs, monkeys, and humans by HPLC-UV (l = 254 nm) revealed only trace levels of three metabolites, designated as M1, M2, and M3 (Table 2 ). In liver microsomes, the three metabolites were formed in a NADPH-dependent fashion, suggestive of a role for P450 or flavin monooxygenase enzymes in the oxidative metabolism of PF-06282999.
PF-06282999 had a retention time (t R ) of approximately 29.0 minutes on HPLC and showed an exact mass of m/z 326.0361 (MH + ). Its MS 2 product ion spectrum showed diagnostic fragment ions at m/z 281.0144, 222.0315, and 155.0256, respectively. The ions at m/z 281 and 222 resulted from neutral losses of formamide and isothiocyanic acid, respectively, whereas the ion at m/z 155 resulted from the formation of a tropylium ion from the chloromethoxybenzene moiety.
Metabolite M1 had a t R of approximately 21.9 minutes on HPLC and an exact mass of m/z 296.0433, which was 30 Da less than that of PF-06282999. The mass spectrum contained fragment ions at m/z 251.0214, 235.0265, and 208.0156. The ion at m/z 208, which was 14 Da less than the parent product ion at m/z 222, suggested a loss of a methyl group from the aromatic ether motif. The fragment ion at m/z 251, which was 30 Da less than the parent ion, suggested loss of a methyl group (214 Da) and replacement of the sulfur (232 Da) with an oxygen atom (+16 Da). This information suggested that M1 resulted from oxidative desulfurization and O-demethylation of the chloromethoxyphenyl moiety.
Metabolite M2 had a t R of approximately 24.1 minutes on HPLC and an exact mass of m/z 312.0204, which was 14 Da less than that of PF-06282999. The mass spectrum contained fragment ions at m/z 266.9986 and 208.0157. The ions at m/z 267 and 208, which were 14 Da less then parent product ions at m/z 281 and 222, suggested that M2 was derived from an O-demethylation of the methoxyphenyl group in PF-06282999.
Metabolite M3 had a t R of approximately 25.7 minutes on HPLC and an exact mass of m/z 310.0589 (MH + ), which was 16 Da less than that of PF-06282999. The mass spectrum contained fragment ions at m/z 265.0372, 222.0314, and 155.0253. The ions at m/z 222 and 155 were also observed in the mass spectrum of the parent compound, indicating that the 6-aryl substituent was unaltered. The fragment ion at m/z 265, which was 16 Da less than the parent product ion m/z 281, suggested oxidative desulfurization of the thiouracil motif. An authentic standard of the proposed metabolite PF-06428486 [2-(6-(5-chloro-2-methoxyphenyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide] was found to have an identical t R and mass spectrum (data not shown).
Because of the lack of metabolic turnover of PF-06282999 in human liver microsomes, human P450 enzymes responsible for oxidative metabolism of PF-06282999 could not be identified using prototypic methodology (e.g., use of selective P450 enzyme inhibitors or dmd.aspetjournals.org recombinant P450 enzymes). Overall, the qualitative biotransformation study suggests that the metabolic routes of PF-06282999 are similar in all species with no evidence of human-specific metabolites. Finally, no glutathione conjugates were detected in human liver microsomal incubations of PF-06282999 in the presence of NADPH and excess glutathione, suggesting that no reactive species were released in the course of oxidative metabolism of PF-06282999.
Human P450 Isozyme Inhibition with PF-06282999. PF-06282999 exhibited no relevant reversible (IC 50 . 100 mM) and timeor NADPH-dependent (IC 50 . 100 mM) inhibitory effects against CYP1A2 (phenacetin-O-dealkylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (paclitaxel-6a-hydroxylation), CYP2C9 (diclofenac-49-hydroxylation), CYP2C19 (S-mephenytoin-49-hydroxylation), CYP2D6 (dextromethorphan-O-demethylation), or CYP3A4/5 (testosterone-6b-hydroxylase, midazolam-19-hydroxylase, and nifedipine oxidase) activities. IC 50 values for reversible and time-dependent inhibition could not be calculated because PF-06282999 did not inhibit any P450 activity more than 30% at the highest concentration tested. Under the present experimental conditions, known P450 isozymespecific inhibitors a-naphthoflavone, orphenadrine, montelukast, sulfaphenazole, modafinil, quinidine, and ketoconazole demonstrated potent competitive inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 activity, respectively, in human liver microsomes (Pfizer data on file). Likewise, metabolismdependent inhibition of P450 activity was also noted with the respective positive control compounds [furafylline (CYP1A2), phencyclidine (CYP2B6), gemfibrozil glucuronide (CYP2C8), tienilic acid (CYP2C9), (S)-fluoxetine (CYP2C19), paroxetine (CYP2D6), and troleandomycin (CYP3A4/5)] in a time-and NADPHdependent fashion (Pfizer data on file).
Absorptive Permeability of PF-06282999. The P app value of PF-06282999 across the Caco-2 cell monolayer (Table 3) in the apical-tobasolateral direction was 2.7 Â 10 26 cm/s, which is comparable to drugs exhibiting moderate oral absorption in humans (Varma et al., 2012) . Under identical experimental conditions, the secretory (B-to-A) permeability of PF-06282999 was 10 Â 10 26 cm/s (efflux ratio = 3.8),
suggesting that PF-06282999 is a substrate for efflux transport. As such, PF-06282999 was found to be a substrate for MDR1 based on bidirectional transport study using the MDCKII-MDR1 cell monolayer with a low efflux ratio of 3.3. This finding is consistent with the reduction in efflux ratio to 1.1 noted in the Caco-2 assay in the presence of the MDR1 inhibitors of verapamil and cyclosporin A. P app,AB in Caco-2 was not affected by the apical pH, with P app,AB at pH 6/7.4 and 7.4/7.4 estimated to be approximately 2.7 Â 10 26 cm/s. In low-permeability paracellular marker, showed absorptive permeability of about 0.9 Â 10 26 cm/s at apical pH of both 6 and 7.4 in the Caco-2 studies. Overall, PF-06282999 demonstrates moderate permeability via both paracellular and transcellular pathways and is a substrate of MDR1 with a low efflux ratio. Hepatobiliary Transport of PF-06282999 in SCHH. The hepatobiliary transport of PF-06282999 was examined in SCHHs (Bi et al., 2006) . Compared with rosuvastatin, PF-06282999 exhibited low total uptake clearance and biliary intrinsic clearance (Table 4 ). The corresponding mean biliary excretion index for rosuvastatin and PF-06282999 was 49% and 11%, respectively. Rifamycin SV, a pan inhibitor of transporters, had a small effect (approximately 25%) on the uptake of PF-06282999; by contrast, rifamycin SV inhibited approximately 90% of rosuvastatin uptake. These observations suggest that the contribution of transporter-mediated hepatobiliary disposition to the overall clearance of PF-06282999 is likely minimal.
PF-06282999 Uptake by Major Human Renal Transporters. Substrate affinity to the major human renal anion (hOAT1 and hOAT3) and cation (hOCT2) transporters was evaluated using HEK 293 cells transfected with hOAT1 , hOAT3 , and hOCT2 transporters. No significant difference in PF-06282999 (0.1-900 mM) uptake by these transporters versus wild-type HEK 293 cells was observed (data not shown), indicating that PF-06282999 is not transported by the major human renal uptake transporters.
Pharmacokinetics of PF-06282999 after Single Doses to Animals. The pharmacokinetic parameters describing the disposition of PF-06282999 after i.v. and p.o. administration in preclinical species are shown in Table 5 . PF-06282999 demonstrated low plasma clearance in mice (10.1 ml/min per kilogram), dogs (3.39 ml/min per kilogram), and monkeys (10.3 ml/min per kilogram) and moderate clearance in rats (41.8 ml/min per kilogram). PF-06282999 was well distributed with Vd ss ranging from 0.5 to 2.1 l/kg in mice, rats, dogs, and monkeys. The terminal elimination t 1/2 ranged from 0.75 to 3.3 hours in the four species. After p.o. administration at a single p.o. dose of 3 or 5 mg/kg, PF-06282999 was rapidly (T max = 0.7-1.70 hours) and well absorbed in mice, rats, dogs, and monkeys, with F values of 100%, 86%, 75%, and 76%, respectively. Table 6 depicts data for renal excretion of unchanged PF-06282999 in preclinical species after i.v. administration. The unbound renal clearance (CL renal,u ) in mice and dogs was lower than the glomerular filtration rate (GFR), suggesting lack of active tubular secretion. However, in rats and monkeys, the unbound CL renal,u values of 28.3 ml/min per kilogram and 3.70 ml/min per kilogram exceeded the GFR of 8.7 ml/min per kilogram and 2 ml/min per kilogram (Lin, 1995) by approximately 3.20-and 1.86-fold, respectively, implying that PF-06282999 is subjected to active tubular secretion mediated by transporters in these species.
Prediction of Human Pharmacokinetics. PF-06282999 was resistant to metabolic turnover in human liver microsomes and hepatocytes under relay conditions, suggesting that metabolism would be inconsequential as a clearance mechanism in human. Furthermore, SCHH studies indicated that hepatobiliary disposition of unchanged PF-06282999 in humans is likely to be insignificant as an elimination mechanism. We therefore speculated that PF-06282999 would be cleared in humans via renal excretion in unchanged form. The observation that all preclinical species exhibited some degree of renal excretion and the similarity in physicochemical properties of PF-06282999 with literature drugs (e.g., acetazolamide, furosemide, captopril, and methotrexate) conducive to renal elimination (Varma et al., 2009) further supported this hypothesis. Consequently, human pharmacokinetics (CL p and Vd ss ) (Table 7) were predicted from singlespecies scaling of animal pharmacokinetics (corrected for plasma protein binding differences) (Frederick et al., 2009) , and estimates of human CL renal (Table 7) were obtained from rat, dog, or monkey CL renal data normalized for plasma protein binding and KBF differences as reported previously (Paine et al., 2011) . Overall, this exercise led to predicted parameters comprising low to moderate CL p (1.8-8.6 ml/min per kilogram or 126 -600 ml/min for a 70-kg adult) and Vd ss (0.4-1.8 l/kg or 28-126 l for a 70-kg adult) and a relatively short predicted t 1/2 of 2.4-2.7 hours, derived from the equation t 1/2 = 0.693 Â Vd ss /CL p . We assumed that the high oral bioavailability of PF-06282999 observed in animals (F $ 75%) would also be translated in humans especially at relatively low doses (20-200 mg) in which absorption would not be negatively affected by solubility and permeability. Considering that PF-06282999 was metabolically stable in human hepatocytes (under relay a Uptake was measured in the presence of rifamycin SV (100 mM).
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conditions), first-pass metabolism was not anticipated to contribute significantly as a deterrence to oral absorption. Clinical Pharmacokinetics of PF-06282999. A total of eight subjects were randomized and treated at each of the four periods with a single p.o. dose of PF-06282999 or placebo. Mean plasma PF-06282999 concentration-time profiles across the studied doses are presented in Fig. 2 . Plasma pharmacokinetic parameters from the noncompartmental analysis are summarized in Table 8 . After single p.o. doses of up to 200 mg PF-06282999 in solution, oral absorption of PF-06282999 was rapid with mean peak plasma concentrations achieved within 1 hour postdose (Fig. 2) . Exposures as estimated by AUC and C max after an p.o. dose were dose proportional up to 200 mg (Fig. 3A) , and the overall mean plasma elimination t 1/2 was comparable at all dose levels with mean values of approximately 4.3-4.4 hours (Table 8) . Renal excretion of PF-06282999 was dose proportional and appeared to be the predominant elimination pathway, with approximately 75% of dose excreted as parent within 24 hours postdose at the 200-mg dose ( Fig. 3B ; Table 9 ). The mean unbound renal clearance of .300 ml/min (renal clearance ranging from 127 to 151 ml/min) exceeded the GFR of 106 6 18 ml/min per 1.73 m 2 reported for healthy adults (Soares et al., 2013) , indicating potential active tubular secretion of PF-06282999. The t 1/2 (4.3-4.4 hours) observed in the clinic was within 2-fold of the predicted value (2.4-2.7 hours).
Discussion
PF-06282999 is a low molecular weight (326 Da), hydrophilic (cLogP = 0.49, LogD 7.4 = 0.81, topological polar surface area = 84.66 Å 2 ), weak acid (pKa = 7.82) (Ruggeri et al., 2015) . Consistent with its physicochemical attributes, PF-06282999 was virtually resistant toward metabolic turnover in NADPH-supplemented liver microsomes and hepatocytes from preclinical species and humans, was devoid of glutathione conjugate formation in human liver microsomes and hepatocytes, and caused no reversible or time-and NADPHdependent inhibition of major human P450 isoforms. Because trace levels of oxidative metabolites were noted in human liver microsomal and hepatocyte incubations of PF-06282999 (Table 2) , we initially speculated that a proportion of the clearance mechanism of PF-06282999 in humans would be dictated by slow metabolism. Metabolic turnover rates for slowly metabolized compounds cannot be estimated in standard hepatocyte assays involving short incubation periods. Recently, a novel human hepatocyte suspension relay assay was used to extend drug residence time in cryopreserved hepatocytes, which provided reliable estimates of in vitro intrinsic clearance for slowly metabolized compounds (Di et al., 2013) . Even under extended incubations, PF-06282999 was stable toward metabolic turnover, which implied that metabolic elimination would be inconsequential as an elimination mechanism in humans. Furthermore, the possibility of hepatobiliary disposition of unchanged PF-06282999 mediated by uptake and efflux transporters was explored in human hepatocytes under sandwich culture conditions (Table 4) . Rifamycin SV, a pan inhibitor of transporters, had minimal effect on the hepatic uptake of PF-06282999, and the biliary excretion index, an indication of extent of biliary secretion, was found to be low. Collectively, hepatic clearance involving metabolizing enzymes and drug transporters has a minimal role in the systemic clearance of PF-06282999.
On the basis of physicochemical properties and membrane permeability, PF-06282999 fit into extended clearance classification system class 3A, where renal clearance is predicted to be the major clearance mechanism in humans (Varma et al., 2015) . Consistent with this, preclinical findings implied that PF-06282999 would be cleared unchanged via renal clearance, which was subsequently confirmed in the first-in-human study (e.g., approximately 75% of the dose excreted unchanged in urine at the 200 mg p.o. dose). Against this backdrop, it is All experiments involving animals were conducted in our AAALAC-accredited facilities and were reviewed and approved by the Pfizer Institutional Animal Care and Use Committee. Pharmacokinetic parameters were calculated from plasma concentration-time data and are reported as means 6 S.D. for n = 3 and maximum values for n = 2. All pharmacokinetics were conducted in male sex of each species (Wistar rats, CD-1 mice, beagle dogs, and/or cynomolgus monkeys). Intravenous doses for PF-06282999 were 1 mg/kg and were administered as a solution. Oral doses for PF-06282999 were 3 or 5 mg/kg and were formulated in 5% HPMC in 20 mM Tris/ 0.5% HPMCAS. a Total CL renal in blood was estimated by multiplying the total CL b with fraction of total i.v. dose of unchanged PF-06282999 excreted in urine. CL b was obtained by dividing CL p by the blood to plasma ratio in the individual animal species (mouse B/P = 1.1, rat B/P = 1.1, dog B/P = 0.91, monkey B/P = 1.2).
Species
b Unbound CL renal in blood was estimated by normalizing total CL renal with the unbound free fraction in blood (mouse = 0.41, rat = 0.41, dog = 0.51, monkey = 0.45), which in turn was obtained by dividing the unbound plasma free fraction by the blood to plasma ratio.
c GFR values in rats, mice, dogs, and monkeys are 8.7, 10, 4, and 2 ml/min per kilogram, respectively.
noteworthy to point out that the percentage of the PF-06282999 dose excreted in the urine after i.v. administration in preclinical species was less than 50%, despite the lack of metabolic turnover detected in the time course of the in vitro assays using animal hepatic tissue (30 minutes of incubation for liver microsomes and 120 minutes for hepatocytes). This may suggest additional in vivo clearance pathways for PF-06282999, such as slow metabolism (low turnover rates in vitro but a relatively higher extent of metabolism in vivo) (Chan et al., 2013) and/or biliary elimination in the preclinical species, especially the rat, where the systemic CL p (41.8 ml/min per kilogram) is in the moderate range. An alternative clearance mechanism may be a possibility to some degree in humans as well. For example, elimination of approximately 75% of the dose in urine at the 200-mg dose suggests that the remainder (25%) of the dose could be cleared through metabolic or biliary excretion routes. However, the possibility remains that 25% of the p.o. dose is not orally absorbed. Radiolabeled mass balance/excretion route studies and absolute oral bioavailability studies with PF-06282999 should shed additional light on the similarities/differences in excretion profile between animals and humans. The predominantly renal elimination pathway of PF-06282999 in humans is not altogether surprising. The physicochemical attributes of PF-06282999 coupled with the measured thermodynamic solubility (crystalline form) of 0.184 mg/ml in phosphate-buffered saline at pH 6.5 and 0.166 mg/ml in unbuffered water, and moderate passive MDCKII-LE permeability (approximately 2.2 Â 10 26 cm/s), would ultimately manifest into a solubility-limited and/or permeability-limited absorption depending on the dose and CL renal as the likely clearance mechanism (Varma et al., 2009 (Varma et al., , 2012 . Renal transporters including hOAT1, hOAT3, and hOCT2 are major transporters expressed on the basolateral membrane involved in the active renal secretion, whereas MDR1, breast cancer resistant protein, multidrug-resistant-associated proteins, and multidrug and toxic compound extrusion 1/2K transporters can potentially mediate secretion across the apical membrane (Masereeuw and Russel, 2001) . PF-06282999 is not a substrate to hOAT1, hOAT3, and hOCT2 but is a substrate of MDR1. Consequently, the .3-fold increase in human CL renal,u (.300 ml/min) of PF-06282999 over the human GFR could be accounted for by an active secretion process in the renal elimination of PF-06282999, mediated by efflux transporter MDR1 coupled with unknown renal uptake transporters. If so, then it is tempting to speculate that species differences in MDR1 expression in the kidney and/or PF-06282999 affinity toward MDR1 would partially account for the differences in CL renal,u exceeding GFR in rats (3.2-fold of GFR), monkeys (1.86-fold of GFR), and humans (3.3-fold of GFR), but not in dogs and mice. Although quantitative information on species difference of MDR1 expression is limited, fairly good correlation was found in the MDR1 efflux activity between humans and monkeys, which could be attributable to high homology of the amino acid sequences (96% similarity) (Takeuchi et al., 2006) . In addition, efflux activity of human MDR1 showed a relatively better correlation with rat Mdr1a and Mdr1b compared with the correlation with mouse or canine efflux activity, although the substrate affinity was maintained across the species. Interestingly, these observations are consistent with the PF-06282999 net secretion noted in humans, rats, and monkeys but not in mice and dogs. Nevertheless, further understanding of the mechanisms involved in the renal secretion and the observed species difference is warranted.
Although transporters can exhibit significant species differences in terms of expression level and functional activity (Chu et al., 2013) , it is noteworthy to point out that human CL renal of 36 structurally diverse drugs was reasonably well predicted using dog CL renal after correcting for plasma protein binding and KBF (Paine et al., 2011) . The clinical pharmacokinetics of PF-06282999 after p.o. administration (20-200 mg) (Table 8) were characterized by a low systemic CL/F (186-197 ml/min or 2.6-2.8 ml/min per kilogram for a 70-kg adult) and a moderate V z /F (68.9-73.7 l or 0.98-1.05 l/kg for a 70-kg adult), which led to a relatively short t 1/2 (4.3-4.4 hours). Normalization of CL/F values for the 20-to 200-mg dose range shown in Table 8 , with approximate F values corresponding to the percentage of dose excreted in urine in a 24-hour period at these doses (Table 9) , yielded CL p ranging from approximately 124 to 149 ml/min or 1.8-2.1 ml/min per kilogram (Table 7) . By contrast, rat CL p overpredicted the human CL p by approximately 4-fold, which implies that clearance mechanisms in addition to renal elimination are operative in the rat and will need additional investigations via metabolic stability assessments in rat hepatocytes under relay conditions and biliary excretion studies.
In a similar fashion, p.o. V z /F (68.9-73.7 l) values were normalized for F equal to the percentage of dose excreted in urine, yielding Vd ss values ranging from 45.9 to 54.8 l or 0.65 to 0.78 l/kg, which were predicted from single-species scaling of dog (0.4 l/kg) and monkey (0.8 l/kg) Vd ss (Table 7) . Despite the subtle nuances in CL p and Vd ss predictions from single-species scaling of animal pharmacokinetics data, it is interesting to note that all preclinical species ultimately predicted a short t 1/2 (2.4-2.7 hours) for PF-06282999 in humans, which is in close proximity to the observed values (3.9-4.2 hours) generated from the CL p and Vd ss estimates at the various dose ranges. Although the human pharmacokinetics predictions utilizing the dog or monkey were fairly accurate, prediction of human CL renal , the predominant clearance mechanism of PF-06282999, using dog and/or monkey CL renal normalized for plasma free fraction and KBF differences and the direct correlations methodology of Paine et al. (2011) , led to .2.5-fold to 3-fold underprediction (predicted human CL renal = 0.6-0.7 ml/min per kilogram for dogs and monkeys, respectively; observed p.o. CL renal in humans = 127-151 ml/min or 1.81-2.15 ml/min per kilogram). By contrast, rat CL renal after correction for plasma unbound fraction and KBF differences led to a predicted human CL renal value of 3 ml/min per kilogram, which was in close proximity to the observed value. Suffice to say, with the exceptions of some anionic compounds, human CL renal was also reasonably well predicted from rat CL renal in the work of Paine et al. (2011) . In addition, CL renal,u exceeding GFR in rats (3.2-fold of GFR) similar to that in humans (3.3-fold of GFR), but not in dogs, could explain a better prediction of human CL renal from rat CL renal but an underprediction using dog CL renal .
On the basis of an analysis of MDCKII-LE permeability versus human intestinal absorption for 105 marketed drugs, compounds with P app of .5 Â 10 26 cm/s are most likely to demonstrate complete oral absorption when solubility is not a limiting factor, whereas a P app range of 2-5 Â 10 26 cm/s represent compounds with human intestinal absorption in the moderate range (approximately 30%-80%) (Varma et al., 2012) . In alignment with the in vitro permeability data, oral bioavailability studies were indicative of good oral absorption (oral F . 75%) in preclinical species at relatively low dose. For the preliminary clinical pharmacokinetics studies at the 20-to 200-mg dose range, PF-06282999 was solubilized in Tris buffer (pH adjusted with NaOH) containing 0.5% hydroxypropyl methylcellulose acetate succinate to prevent precipitation to eliminate any potential solubility-limited absorption. PF-06282999 was rapidly absorbed (T max = 0.5-0.75 hours) in humans when administered orally as a solution, which suggested good permeation in the upper gastrointestinal tract. Likewise, on the basis of the renal excretion data (approximately 75% of the 200-mg dose excreted unchanged in urine), it is safe to assume that the oral F of PF-06282999 is at least 75% at the 200-mg dose.
In conclusion, this study provides key information regarding the disposition characteristics of PF-06282999, a novel mechanism-based inactivator of MPO, in preclinical species and humans. Renal clearance of unchanged PF-06282999 emerged as the principal clearance mechanism in humans, a phenomenon that was consistent with the physicochemical and permeability characteristics as defined by the extended clearance classification system. Furthermore, the human pharmacokinetics of PF-06282999 were reasonably well predicted from single-species scaling of dog and/or monkey pharmacokinetics data, corrected for plasma free fraction differences. Selective inhibition of MPO relative to other peroxidases (e.g., thyroid peroxidases), renal elimination with minimal hepatic oxidative metabolism, and absence of mechanism-based P450 inhibition by PF-06282999 provides a strong rationale for mitigating idiosyncratic toxicity and drug-drug interaction risks with a drug candidate containing a structural alert.
